Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

CGEM
Cullinan Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
Aug 3, 2026 3:59:54 PM EDT
16.26USD-1.455%(-0.24)386,582
0.00Bid   0.00Ask   0.00Spread
Pre-market
Aug 3, 2026 9:12:30 AM EDT
16.69USD+1.152%(+0.19)414
After-hours
Aug 3, 2026 4:00:30 PM EDT
16.25USD-0.062%(-0.01)78,478
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
06:33AM EST  Cullinan Oncology Forms Strategic Collaboration Agreement With Mount Sinai To Advance Oral HPK1 Protein Degrader For Cancer Treatment   Benzinga
06:30AM EST  Collaboration to identify and advance best-in-class HPK1 protein degraders   GlobeNewswire Inc
Jan 5, 2022
09:00AM EST  Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan) today announced that it will present at the following virtual healthcare conferences in January:   GlobeNewswire Inc
Jan 4, 2022
07:11AM EST  FDA Grants Breakthrough Therapy Designation For Cullinan Oncology's CLN-081 In Patients With Locally Advanced Or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer   Benzinga
07:00AM EST  FDA Grants Breakthrough Therapy Designation for Cullinan   GlobeNewswire Inc
Dec 16, 2021
01:04PM EST  Cullinan Oncology Posts Updated Data for CLN-081 in NSCLC EGFR Exon 20 Patients   Benzinga
08:20AM EST  The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street   Benzinga
06:36AM EST  Cullinan Oncology Announces Updated Phase 1/2a Data For CLN-081 In NSCLC EGFR Exon 20 Patients; Co. Reports 'Continued high response rate with favorable safety and tolerability profile observed in heavily pre-treated patients at 100mg BID'   Benzinga
06:32AM EST  Cullinan Oncology Announces Updated Phase 1/2a Data For CLN-081 In NSCLC EGFR Exon 20 Patients   RTTNews
06:30AM EST  CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID   GlobeNewswire Inc
Dec 13, 2021
07:00AM EST  Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies, will provide a clinical update on CLN-081 during a webinar on Thursday, December 16, 2021, at 8:00 a.m. ET.   GlobeNewswire Inc
Nov 22, 2021
12:37PM EST  Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies, today announced that it will be participating in the 4th Annual Evercore ISI HealthconX Conference from November 30th to December 2nd, 2021.   GlobeNewswire Inc
Nov 9, 2021
11:29AM EST  Cullinan Oncology Q3 EPS $(0.40) Up From $(0.50) YoY   Benzinga
06:45AM EST  Cullinan Pearl clinical update, including data from patients enrolled in the Phase 2a expansion 100 mg BID cohort, planned for fourth quarter 2021   GlobeNewswire Inc
Oct 18, 2021
07:11AM EDT  Cullinan Oncology Announces Nadim Ahmed President and CEO, Current CEO Resigned   Benzinga
07:00AM EDT  Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer   GlobeNewswire Inc
Oct 1, 2021
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 23, 2021
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
Sep 8, 2021
04:01PM EDT  Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan) today announced its participation in the following upcoming investor conferences:   GlobeNewswire Inc
Aug 10, 2021
02:42PM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
09:13AM EDT  Cullinan Oncology Q2 Loss Per Share $0.44 Vs Loss $0.36 Last Year   RTTNews
06:35AM EDT  Cullinan Management Q2 EPS $(0.36) Up From $(0.44) YoY   Benzinga
06:30AM EDT  Follow-up Cullinan Pearl data from Phase 1 portion of ongoing trial showed increased disease control rate (DCR) of 92% in the 100mg dose cohort   GlobeNewswire Inc
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jun 29, 2021
08:19AM EDT  Cullinan Oncology Gets FDA Clearance Of IND Application For CLN-619 For Solid Tumors   RTTNews
08:04AM EDT  Cullinan Oncology Receives FDA Clearance Of Investigational New Drug Application For CLN-619 For Treatment Of Solid Tumors   Benzinga
08:00AM EDT  -- CLN-619 will be the first MICA/B-targeted antibody to enter human clinical trials -- Cullinan will initiate a FIH trial in 3Q21, including a dose escalation cohort followed by dose expansion cohorts as a monotherapy and in combination with checkpoint inhibitor therapy   GlobeNewswire Inc
Jun 24, 2021
08:12AM EDT  The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO   Benzinga
Jun 23, 2021
07:35AM EDT  The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway   Benzinga
Jun 18, 2021
07:46AM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Jun 7, 2021
08:41AM EDT  Cullinan Oncology Says FDA Has Cleared IND Application For CLN-049 Antibody   RTTNews
08:32AM EDT  Cullinan Oncology Receives Investigational New Drug Clearance From FDA For CLN-049, a FLT3 x CD3 Bispecific Antibody For Treatment Of Relapsed/Refractory AML   Benzinga
08:30AM EDT  Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that the U.S. Food and Drug Administration (FDA) has cleared Cullinan Florentines IND application for CLN-049, a FLT3 x CD3 bispecific antibody for the treatment of relapsed/refractory acute myeloid leukemia (AML).   GlobeNewswire Inc
07:47AM EDT  Morgan Stanley Maintains Overweight on Cullinan Oncology, Raises Price Target to $43   Benzinga
Jun 4, 2021
12:23PM EDT  HC Wainwright & Co. Maintains Buy on Cullinan Oncology, Raises Price Target to $55   Benzinga
12:12PM EDT  Mid-Day Market Update: Gold Rises Over 1%; Harpoon Therapeutics Shares Plummet   Benzinga
10:27AM EDT  SVB Leerink Maintains Outperform on Cullinan Oncology, Raises Price Target to $54   Benzinga
10:19AM EDT  Shares of Cullinan Oncology Inc. (CGEM) are surging over 18% Friday morning, after the company announced that ongoing Phase 1/2a trial of CLN-081 in Non-Small Cell Lung Cancer or NSCLC patients continues to show acceptable overall safety and tolerability, with encouraging GI toxicity profile.   RTTNews
09:22AM EDT  Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl's CLN-081 in NSCLC EGFR Exon 20 Patients   Benzinga
09:00AM EDT  Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan   GlobeNewswire Inc
May 21, 2021
02:49PM EDT  Mid-Afternoon Market Update: Dow Rises 150 Points; VF Corp Shares Fall On Downbeat Earnings   Benzinga
12:19PM EDT  Mid-Day Market Update: Nasdaq Turns Lower; Annovis Bio Shares Surge   Benzinga
10:22AM EDT  Mid-Morning Market Update: Markets Open Higher; Deere Beats Q2 Estimates   Benzinga
08:00AM EDT  Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that Jon Wigginton, M.D. is stepping down from his day-to-day role as Chief Medical Officer, and will assume the role of Chairman of the companys Scientific Advisory Board (SAB) and Senior Advisor to the CEO.   GlobeNewswire Inc
May 19, 2021
05:25PM EDT  Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021   Benzinga
05:00PM EDT  Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that it will provide a clinical update on CLN-081 during a webinar on Friday, June 4th, 2021 at 10:30 am ET (Pearl Clinical Update Webinar).   GlobeNewswire Inc
May 14, 2021
06:35AM EDT  Cullinan Management Q1 EPS $0.00 vs $(0.27) In Same Qtr. Last Year, Sales $18.94M   Benzinga
06:30AM EDT  Continued advancement of broad portfolio, highlighted by initiation of Phase 2a dose expansion of Cullinan Pearl in NSCLC patients with EGFRex20ins mutations   GlobeNewswire Inc
Apr 27, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2021   Benzinga
06:18AM EDT  Morgan Stanley Upgrades Cullinan Oncology to Overweight   Benzinga
Apr 19, 2021
10:13AM EDT  Morgan Stanley Maintains Equal-Weight on Cullinan Oncology, Raises Price Target to $40   Benzinga
Apr 7, 2021
10:08AM EDT  Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan) announced today that the companys Chief Financial Officer, Jeff Trigilio, will present at the upcoming 20th Annual Needham Virtual Healthcare Conference.   GlobeNewswire Inc
Mar 30, 2021
12:59PM EDT  HC Wainwright & Co. Maintains Buy on Cullinan Oncology, Raises Price Target to $48   Benzinga
06:17AM EDT  Cullinan Oncology FY20 EPS $(3.23), Up From $(5.48) YoY   Benzinga
06:15AM EDT  Pipeline Progress: Clinical and preclinical programs continue to advance, with encouraging initial Cullinan Pearl data and additional INDs to be filed in 2021 for immuno-oncology assets Cullinan Florentine and Cullinan MICA   GlobeNewswire Inc
Mar 11, 2021
08:19AM EST  The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena   Benzinga
Mar 10, 2021
07:26AM EST  The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link   Benzinga
Mar 3, 2021
07:46AM EST  The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study   Benzinga
Mar 2, 2021
09:48AM EST  Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announced that the companys Chief Executive Officer, Owen Hughes, will present at the upcoming H.C. Wainwright Global Life Sciences Conference.   GlobeNewswire Inc
08:01AM EST  The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data   Benzinga
Feb 22, 2021
07:55AM EST  Cullinan Management Announces Enrollment Expansion In CLN-081 NSCLC EGFRex20ins Phase 1/2a Trial   RTTNews
07:32AM EST  Cullinan Management Says Withdraws IND Application For CLN-049 In Relapse/Refractory AML; Says Expands Enrollment In CLN-081 NSCLC EGFRex20ins Phase 1/2a Trial   Benzinga
07:30AM EST  Cullinan Management, Inc. Announces Business Update   GlobeNewswire Inc
Feb 2, 2021
10:07AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2021   Benzinga
08:33AM EST  Evercore ISI Group Initiates Coverage On Cullinan Management with Outperform Rating, Announces Price Target of $55   Benzinga
07:44AM EST  SVB Leerink Initiates Coverage On Cullinan Management with Outperform Rating, Announces Price Target of $52   Benzinga
07:42AM EST  Morgan Stanley Initiates Coverage On Cullinan Management with Equal-Weight Rating   Benzinga
Feb 1, 2021
12:12PM EST  Cullinan Management shares were trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a price target of $47 per share.   Benzinga
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2021   Benzinga
06:07AM EST  HC Wainwright & Co. Initiates Coverage On Cullinan Management with Buy Rating, Announces Price Target of $47   Benzinga
Jan 12, 2021
10:02PM EST  Cullinan Management Closes IPO; Gross Proceeds Of Offering $287.4 Mln, Before Deducting Underwriting Discounts   RTTNews
09:43PM EST  Cullinan Management Announces Closing of Initial Public Offering   GlobeNewswire Inc
Jan 8, 2021
12:14AM EST  Please note that the embedded hyperlinks in the press release below have been corrected from a release issued under the same headline earlier today.   GlobeNewswire Inc
Jan 7, 2021
09:53PM EST  Cullinan Management Prices Upsized IPO Of 11.90 Mln Shares At $21.00/shr   RTTNews
09:03PM EST  Cullinan Management Announces Pricing of Upsized Initial Public   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC